IKNA : Insider Transactions for Ikena Oncology, Inc. | J3SG

Sign in:	Email	Password save:

		Company Reports
Find Symbol

Recent: Companies Filers Institutions

Membership is free, please Sign Up.

My Recent Searches

Help

Roster

Institutions

Add To Portfolo/Alerts

Get Insiders for :

Ikena Oncology, Inc. (IKNA)

$0.00 0.00 (0.00%) as of 4:30 Tue 11/30

Download

Exchange:

N/A

Security Type:

N/A

Shares Out:

48,260,000

Market Cap:

N/A

Last Volume:

0

Avg Vol:

0

52 Week Range:

$ - $

Level I Sector:

N/A

Level II Sector:

N/A

Level III Sector:

N/A

Member Indexes:

Rankings:

Insider 3 Months : -

Insider 6 Months : -

Insider 3/6 Months : -

Guru Rank Number : -

Guru Rank Value : -

Guru Occurances : -

Company Profile Ikena Oncology is a targeted oncology company developing medicines tailored to biomarker-defined patient groups. Co.'s programs are across the Hippo pathway, RAS pathway, and key immune signals in the tumor-microenvironment, with approaches to targeting both cancer driving targets and mechanisms of resistance to targeted therapies. Co.'s primary targeted oncology product candidate, IK-930, is an oral small molecule inhibitor of the transcriptional enhanced associate domain transcription factor in the Hippo signaling pathway. Co.'s clinical-stage programs also include product candidates in development to target immune signaling in the tumor microenvironment.

D/I:

D is for direct shares.
I is for indirect shares.

D/I refers to the Direct or Indirect shares traded vs. held.

Forms:

A Form 4 is a form filed by an insider to indicate a change in ownership.

A Form 3 is a form filed by an insider to indicate an initial ownership of a security.

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.

Actions:

B	Buy
S	Sell
OE	Option Exercised
A	Acquired
D	Disposed
AB	Automatic Buy
AS	Automatic Sell
IO	Initial Ownership

Download:

Download only Transactions Forms. (Default)

Download only Summary Infomation.

Download both Transactions and Summary Data

Summary (Direct Transactions Only)	3 Months	6 Months	12 Months	24 Months
Total Shares Bought	0	0	0	0
Total Buy Value	$0	$0	$0	$0
Total People Bought	0	0	0	0
Total Buy Transactions	0	0	0	0
Total Shares Sold	0	0	0	504,450
Total Sell Value	$0	$0	$0	$2,256,040
Total People Sold	0	0	0	2
Total Sell Transactions	0	0	0	6
End Date	2024-01-28	2023-10-27	2023-04-28	2022-04-28

Adjust Filter Settings

Records found: 44

Page 1 of 2

Filer's Name

Relation Title

Off-Dir-10%

D/I

Rank

3m +/-

Form

Director

– • –

2023-08-04

4/A

A

$0.00

$0

I/I

153,121

5,582,144

-

Orbimed Genesis Gp Llc

Director

– • –

2023-08-04

4/A

A

$0.00

$0

I/I

153,121

5,582,144

-

Orbimed Genesis Gp Llc

Director

– • –

2023-08-04

4

A

$0.00

$0

I/I

153,121

2,251,218

-

Director

– • –

2023-08-04

4

A

$0.00

$0

I/I

153,121

2,251,218

-

Director

– • –

2022-06-24

4

S

$4.37

$803,975

I/I

(162,000)

2,098,097

-

Orbimed Genesis Gp Llc

Director

– • –

2022-06-24

4

S

$4.37

$803,975

I/I

(162,000)

2,098,097

-

Director

– • –

2022-06-23

4

S

$3.71

$86,884

I/I

(23,419)

1,936,097

-

Orbimed Genesis Gp Llc

Director

– • –

2022-06-23

4

S

$3.71

$86,884

I/I

(23,419)

1,936,097

-

Director

– • –

2022-06-22

4

S

$3.55

$237,161

I/I

(66,806)

1,912,678

-

Orbimed Genesis Gp Llc

Director

– • –

2022-06-22

4

S

$3.55

$237,161

I/I

(66,806)

1,912,678

-

Chief Business Officer

• – –

2022-01-18

4

OE

$2.94

$253,800

D/D

71,786

100,578

-

Zhang Xiaoyan Michelle

Chief Scientific Officer

• – –

2022-01-11

4

AS

$12.00

$11,568

D/D

(964)

44,475

-

Zhang Xiaoyan Michelle

Chief Scientific Officer

• – –

2022-01-11

4

OE

$2.15

$2,069

D/D

964

45,439

-

Zhang Xiaoyan Michelle

Chief Scientific Officer

• – –

2022-01-10

4

AS

$12.00

$432

D/D

(36)

44,475

-

Zhang Xiaoyan Michelle

Chief Scientific Officer

• – –

2022-01-10

4

OE

$2.15

$77

D/D

36

44,511

-

Formela Jean Francois

Director

– • –

2021-12-14

4

S

$14.00

$83,426

I/I

(5,959)

1,241,935

-

Atlas Venture Associates Opportunity I, Llc

10% Owner

– – •

2021-12-14

4

S

$14.00

$83,426

D/D

(5,959)

1,241,935

-

Formela Jean Francois

Director

– • –

2021-12-13

4

S

$14.64

$121,951

I/I

(8,330)

1,247,894

-

Atlas Venture Associates Opportunity I, Llc

10% Owner

– – •

2021-12-13

4

S

$14.64

$121,951

D/D

(8,330)

1,247,894

-

Formela Jean Francois

Director

– • –

2021-12-10

4

S

$15.03

$180,195

I/I

(11,989)

1,256,224

-

Zhang Xiaoyan Michelle

Chief Scientific Officer

• – –

2021-12-10

4

S

$14.76

$14,760

D/D

(1,000)

44,475

-

Zhang Xiaoyan Michelle

Chief Scientific Officer

• – –

2021-12-10

4

OE

$2.15

$2,146

D/D

1,000

45,475

-

Atlas Venture Associates Opportunity I, Llc

10% Owner

– – •

2021-12-10

4

S

$15.03

$180,195

D/D

(11,989)

1,256,224

-

Formela Jean Francois

Director

– • –

2021-03-30

4

B

$16.00

$2,000,000

I/I

125,000

874,634

2.1

-

Atlas Venture Associates Opportunity I, Llc

10% Owner

– – •

2021-03-30

4

B

$16.00

$2,000,000

I/I

125,000

874,634

1.5

-

44 Records found	1 2	Page 1 of 2

	Transaction Code Key:				Ownership Code Key
	B	- Buy	AB	- Automatic Buy	D	- Direct Ownership
	S	- Sell	AS	- Automatic Sell	I	- Indirect Ownership
	OE	- Options Exercised	A	- Acquired
	IO	- Initital Ownership	D	- Disposed

Copyright © 2024 j3sg.com | Disclaimer & Terms of use Products & Service About Us Contact Us

Summary:

Chart:

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.